Vietnam Holding added to FTSE All-Share Index as Ocado and St James’s Place removed from FTSE 100

Following a period of strong performance and a narrowing discount by Vietnam Holding, the investment trust has been added to the FTSE All-Share index in the latest quarterly reshuffle.

The trust has significantly outperformed its benchmark over the past year, and its share price appreciation means Vietnam Holding now joins the ranks of London’s top 500 or so companies by market cap in the FTSE All-Share index.

“Vietnam Holding’s share price has reached a record high recently driven by the combination of strong Net Asset Value growth and a narrowing of the discount between the share price and the Net Asset Value,” said Craig Martin, Chairman of Dynam Capital, the manager of Vietnam Holding.

“We see great growth prospects for the Vietnam economy in the years ahead. The portfolio is attractively priced and provides UK investors with an easy way to access an exciting and dynamic emerging market.”

The Vietnam Holding NAV is up 28.7% over the past year, driven by underlying Vietnam economic expansion and particular strength in exports as the country is increasingly seen as an alternative to China for manufacturing operations.

The latest reshuffle of FTSE indices saw Ocado, RS Group, and St James’s Place dumped out of the FTSE 100 to be replaced by Darktrace, LondonMetric, and Vistry.

ITM Power shares rise with revenues set to triple

ITM Power shares rose on Thursday after the Green Hydrogen specialist announced that it expected a tripling of profits and halving of losses in the full year.

Ahead of its preliminary results scheduled for release on August 15th, 2024, ITM Power PLC has provided a summary of its financial performance for the 12 months ending April 30th, 2024. The company’s revenue is expected to be in the range of £16.0m to £16.5m, which falls within the guidance range of £10m to £18m and represents a remarkable threefold increase compared to the previous year.

The expected financial results, subject to audit, also indicate an adjusted EBITDA loss between £39.0m to £44.0m. While this figure is better than the guidance of £45m to £50m, it still represents a year-on-year reduction of more than 50%, reflecting the company’s ongoing efforts to improve its financial performance.

Furthermore, ITM Power PLC reported a net cash position of £230m at the year-end, surpassing the guidance range of £200m to £220m. This positive result is attributed to the stringent cost and capital disciplines that have now become ingrained in the company’s DNA, demonstrating its commitment to financial prudence and sustainability.

“During the year, we completed our 12-month plan, transforming ITM into a credible delivery organisation, and we have attained a positive operating rhythm of deploying products to our customers,” said Dennis Schulz, CEO of ITM.

“We grew revenue more than threefold and halved our losses, and in line with our strategic priorities, we managed our cash carefully. I am pleased with our progress, and look forward to providing further details, including guidance for the current year, at the time of our preliminary results announcement in August.”

Avacta – research house sees peptide-drug company reporting 75% deeper loss this year, but it values shares at over four times current price

Avacta (LON:AVCT), the £148m-valued life sciences company targeting cancer treatments and diagnostics, is expected to see an adjusted pre-tax loss of some £41.3m (£23.6m), on the back of just a small increase in revenues to £23.9m (£23.2m) for the year to end December this year.

The company has two divisions: a clinical stage oncology biotech division harnessing proprietary therapeutic platforms to develop novel, highly targeted cancer drugs; and a diagnostics division focused on supporting healthcare professionals.

Avacta owns two novel technology platforms: pre|CISION and Affimer.

pre|CISION improves potency and reduces toxicity of cancer drugs by only activating them inside the tumour.

Affimer proteins are antibody mimetics being developed as diagnostic reagents and oncology therapeutics.

It is claimed that successful clinical trials would be transformative for Avacta. 

Research Experts Give 188p A Share Value

With expertise in the biotech, medtech, specialty pharma and consumer health sectors, the research team at Trinity Delta covers the healthcare and life sciences sectors.

Its report on Avacta, published today, values the company using a sum-of-the-parts, which includes a risk-adjusted net present value (rNPV) of the lead clinical asset AVA6000, an aggregate rNPV for the remainder of the proprietary platforms (pre|CISION and Affimer), and a DCF valuation for the Diagnostics business, which are netted against operating costs.

It has increased its valuation to £675m for the company, worth some 188p a share which is more than four times the current share price of 41p.

Ittybit secures £1.5m in funding round led by Mercuri and Sure Valley Ventures

Ittybit has secured £1.5m in a funding led by Mercuri and Sure Valley Ventures to help propel growth in their mission to revolutionise AI-led file management.

As online content consumption soars, there is a growing demand for managing digital files, particularly video. Salford-based Ittybit streamlines this process with tools designed to simplify the uploading, storing, and delivery of large video, image, and audio files.

Ittybit’s media management solution has delivered impressive results for early customers. Strength:Lab slashed bandwidth costs by 80%, while a major podcast transcribed over 1,000 episodes, enhancing search and recommendations.

Early adopters have successfully managed over 100,000 images and 5,000 hours of user-generated video, showcasing Ittybit’s scalability and reliability.

“Ittybit’s proprietary Machine Learning solution is transforming the costs of hosting media for both SMEs and Enterprises globally,” said Brian Kinane, Founding Partner, Sure Valley Ventures.

“We are delighted to back a Manchester-based, cutting-edge AI company who are well-positioned to execute on their mission to democratise media hosting, at a time when the innovation of multimodal large language models is enabling content creation at an unprecedented scale.”

SolGold – one of the world’s largest undeveloped copper-gold projects sees major exploitation contract being signed off

SolGold, the developer of a world-class copper-gold project in Northern Ecuador, has announced that it has signed off a significant contract for its flagship Cascabel Project that covers an area of approximately 50 square kilometres located in Imbabura province.

It is a mineral exploration and development company, that explores for and develops mineral properties in Ecuador, Australia, Chile, and Solomon Islands, primarily exploring for copper, gold, silver, and molybdenum deposits.

The Important EC Contract

The Exploitation Contract establishes the legal and financial terms and conditions for the development of the Cascabel Project by the Brisbane, Australia-based £272m capitalised SolGold (Lon and TSX: SOLG).

It covers key contract items such as: not less than a 50% share of the benefits going to the Ecuador Government; that there will be a renewable 33-year contract for copper, gold and silver production; that SolGold will make a total of $75m royalty payments, of which $25m is an advance sum; the Government Royalty will be on net smelter revenues ranging from 3%-8% based on mineral and price; a mechanism to balance out the effects of any changes in Ecuador fiscal policy, taxes, laws and other regulations; investor protection rights; and importantly that it develops the autonomy and freedom of the company to make its commercial decisions. 

SolGold shares, which were trading at 19.20p this time last year, before easing back to 6.02p in early March this year, are currently just 9.07p.

The UK produces most Fintech Unicorns in Europe, according to Dealroom

A new report issued by Dealroom confirmed the UK produces more Fintech Unicorn companies than any other European country. Four times as many to be precise. 

The report issued by Dealroom in conjunction with Armstrong International found that the UK is a leader in creating Fintech companies that attract valuations of $1bn or more. 

The UK is home to 52 of Europe’s 121 billion-dollar Fintech companies compared to just 13 in France and 12 in the Netherlands. 

Data collected by Dealroom found European Fintechs were worth a total of $445bn compared to $433bn in 2023, but down from a high of $470bn in 2021.

A Fintech funding ecosystem of leading VCs and UK-based sophisticated individual investors has helped nurture Fintech giants, including Monzo, worth $5.4bn, and SumUp, which has raised a total of $662m in equity funding and $1.5bn in debt.

Other UK Fintech success stories include Revolut, Starling Bank, and Zopa. You will note all of the companies mentioned are yet to IPO, opting to remain private companies.

In 2023, transaction values for UK Fintechs fell to £9.75bn, down 34% from £14.82bn in 2022 amid a wider slowdown in capital markets, according to KPMG.

Still, UK Fintechs raised more than those in France, Germany, China, India, Brazil and Canada combined.

AIM movers: Pantheon Resources Alaska state deal and Jersey Oil & Gas Buchan delay

1

Pantheon Resources (LON: PANR) has entered a gas sales precedent agreement with the state-owned Alaska Gasline Development Corporation, which is developing the Alaska LNG project. This is designed to supply Alaska and export up to 20 million tonnes of LNG each year. Pantheon Resources would supply up to 500 mmcf/day of gas at a maximum base price of $1/mmbtu. There are plans to increase the scale of the Ahpun development. The share price jumped 29.4% to 36.3p.

Restaurants operator Tasty (LON: TAST) gained court approval of its restructuring plan on Tuesday afternoon. Tasty has got out of the leases of 23 sites. This leaves 38 restaurants, which are predominantly the Wildwood brand. This should improve EBITDA by up to £2.1m between 2003 and 2005. The share price continued its rise today and it is up a further 29.2% to 1.55p.

Insig AI (LON: INSG) has raised a further £813,000 at 12.5p/share. New Insig AI chief executive Richard Bernstein had subscribed £100,000 at 20p/share. Insig AI recently bought a 5.45% stake in AI and blockchain company ImpactScope OU for 900,000 shares at 13.75p each and Insig Ai has an option to subscribe for more shares. The share price improved 15.7% to 14.75p.

Empire Metals (LON: EEE) considers further positive exploration results as a major development for the Pitfield prospect. There is rutile at surface, and it should be easy to mine. Titanium dioxide mineralisation gets more prevalent at lower depths. This should improve project economics. The share price increased 13.5% to 11.75p.

FALLERS

Jersey Oil & Gas (LON: JOG) has progressed its FEED programme for the Buchan development in the North Sea, but decisions have been put on hold until after the General Election. The first offshore survey has been completed. The final investment decision is expected in 2025, dependent on clarity over ongoing UK government policy, which means first oil could be in 2027. Jersey Oil & Gas contributes 20% of the joint venture project costs. The share price dipped 16.7% to 125p.

There is another fundraising by cancer biopsy company Angle (LON: AGL) is raising £8.5m at 15p/share and could raise up to £2.06m more via an open offer. The cash will be spent on additional staff, commercial development, developing lab capacity. Angle says that it should reach cash flow breakeven by the end of 2025. There was £16.2m in cash at the end of 2023. In 2023, revenues more than doubled to £2.2m and the loss was £20.1m. Interim revenues are expected to be more than £1m. The share price declined 12.5% to 15.75p.

Seed Innovations (LON: SEED) has completed its share buyback programme. This used up £510,000 on top of the £2m dividend. That followed the disposal of its Leaf Gaming stake for £2.4m. The share price declined 7.14% to 1.95p. There has been a 9.3% share price decline so far this year, but that is not adjusted for the 1p/share special dividend.

Lupus treatment developer ImmuPharma (LON: IMM) reported a reduction in loss from £4.46m to £3.42m. It has taken longer than thought to approach commercialisation of the Lupus treatment Lupuzor. There should be enough evidence to move to a phase 3 clinical study. There was cash of £200,000 at the end of 2023. ImmuPharma raised £1.5m from the sale of its shares in Aquis-quoted skincare company Incanthera, which was valued at £600,000 at the end of 2023, although it retains warrants. The share price slipped 5.36% to 2.47p.

FTSE 100 gains with eyes on European and Canadian rate cuts

The FTSE 100 gained on Wednesday as investors looked forward to the first interest rate cuts by major western central banks since the global hiking cycle started around two years ago.

The European Central Bank is widely predicted to cut interest rates at its meeting tomorrow and hopes will be this opens the doors to the Bank of England and Federal Reserve to follow suit.

London’s leading index was 0.2% higher at 8,251 at the time of writing.

“The FTSE 100 moved higher on Wednesday with a broad spread of companies across multiple sectors enjoying solid gains,” said AJ Bell investment director Russ Mould.

“A recent fall in oil prices may not be good news for two big energy firms which bestride the index but for others it means a potential reduction in inflationary pressures and more scope for central banks to begin easing rates.

“The Bank of Canada and European Central Bank are expected to steal a march on the Federal Reserve and Bank of England by cutting rates over the next 24 hours. The market will also weigh US employment data and a reading from the services sector across the Atlantic.”

Investor’s trading week will really heat up tomorrow, with interest rate decisions being closely followed by Non-Farm Payrolls on Friday – the last major economic data reading before the Federal Reserve makes its interest rates decision next week.

Markets had a hint of optimism going into the announcements, and there was a clear risk-on tone to trade in UK stocks. The gains were broad on Wednesday, with many cyclical sectors enjoying a boost.

St James’s Place was again the best performer as the beleaguered wealth manager enjoyed buying pressure from bargain hunters. Bargain hunters also took a shine to GSK, gaining 1.9%, after it sank on Monday due to litigation concerns.

There was a mild bid for housebuilders ahead of the rate decisions. Persimmon added 0.6% and Taylor Wimpey rose 1.7%.

Angus Energy restarts production at Brockham well in Surrey

Angus Energy shares rose on Wednesday after the company announced that is has successfully restarted production at its Brockham Oil Field in Surrey, aligning with the company’s strategy to revive operations at the site.

In late May, Angus Energy completed the workover of the Brockham 2Y well, a crucial step in reinstating production from the field. The workover involved installing a new pump in the well and conducting repairs and upgrades to the surface equipment.

After a period of flow to clean up the well, it is now back online, producing approximately 120 barrels per day (bbls/day) of total fluid, with 40% currently consisting of oil.

Investors should note Angus Energy said they will closely monitor the well’s performance over the coming days to assess its future production potential.

Angus Energy has a 80% interest in the Brockham Oil Field.

“As we stated in our last strategic update, Angus intends to expand production through organic and inorganic growth. This is the first step of that journey. We are very pleased with our progress at the Brockham Field to resume production,” said Richard Herbert, Angus Energy CEO.

“The workover was completed safely and on schedule and budget, with the new pump starting up on the 28th May. The well is now producing oil in excess of management’s predicted flowrates and with the present surface configuration is expected to sustain 30-40 bbls/day of oil, with potential to increase further with operational improvements.”

Angus Energy shares were 6% higher at the time of writing.

WH Smith shares rise as travel boom boosts sales

The travel boom has far-reaching benefits, and the propensity for holidaymakers to spend freely on holidays and their holiday experience has helped increase WH Smith sales.

WH Smith’s UK travel unit sales rose 9% in the 13 weeks to 1 June as the business transitions to being a ‘one-stop-shop’ for travel essentials for which it can charge a premium.

Anyone who has reluctantly bought a bottle of water from WH Smith at an airport will have a good idea of the company’s strategy. WH Smith has successfully placed stores in locations where potential customers have little option but to pay the higher price they demand. In addition to airports, WH Smith has targeted rail terminals, where sales rose 8%, and hospitals. Hospital sales surged 14%.

North American sales grew 3% while Rest of the World jumped 15%.

In the UK High Street division, which includes online sales, total revenue was down 4% for the 13 weeks ending June 1, 2024. However, the store network performed well, with LFL revenue flat compared to the same period last year.

Five new Toys “R” Us shop-in-shops have been successfully opened within existing stores and plans are in place to open an additional 25 shop-in-shops by the end of the financial year.

“What’s really interesting is how WH Smith is helping to revive the Toys R Us brand. It is slowly converting parts of its UK stores to house sections dedicated to toys under this retro name and it looks like the strategy is paying off,” said AJ Bell investment director Russ Mould.

The company has maintained guidance for the year and says it is well positioned for the peak summer trading period.

WH Smith shares were 3% higher at the time of writing on Wednesday.